Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic DNA Vaccine Targeting Mycobacterium tuberculosis Persisters Shortens Curative Tuberculosis Treatment.
Karanika S, Wang T, Yilma A, Castillo JR, Gordy JT, Bailey H, Quijada D, Fessler K, Tasneen R, Rouse Salcido EM, Harris HT, Bates RE, Ton H, Meza J, Li Y, Taylor AD, Zheng JJ, Zhang J, Peske JD, Karantanos T, Maxwell AR, Nuermberger E, Markham RB, Karakousis PC. Karanika S, et al. Among authors: nuermberger e. bioRxiv [Preprint]. 2024 Sep 7:2024.09.03.611055. doi: 10.1101/2024.09.03.611055. bioRxiv. 2024. PMID: 39282461 Free PMC article. Preprint.
Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models.
Pertinez H, Kaushik A, Curley P, Arshad U, El-Khateeb E, Li SY, Tasneen R, Sharp J, Kijak E, Herriott J, Neary M, Noë M, Flexner C, Nuermberger E, Owen A, Ammerman NC. Pertinez H, et al. Among authors: nuermberger e. bioRxiv [Preprint]. 2024 Mar 6:2024.03.03.583160. doi: 10.1101/2024.03.03.583160. bioRxiv. 2024. PMID: 38496644 Free PMC article. Preprint.
Enhanced dynamic covalent chemistry for the controlled release of small molecules and biologics from a nanofibrous peptide hydrogel platform.
Pogostin BH, Wu SX, Swierczynski MJ, Pennington C, Li SY, Vohidova D, Seeley EH, Agrawal A, Tang C, Cabler J, Dey A, Veiseh O, Nuermberger EL, Ball ZT, Hartgerink JD, McHugh KJ. Pogostin BH, et al. Among authors: nuermberger el. bioRxiv [Preprint]. 2024 May 23:2024.05.21.595134. doi: 10.1101/2024.05.21.595134. bioRxiv. 2024. PMID: 38826442 Free PMC article. Preprint.
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.
Ernest JP, Ni Goh JJ, Strydom N, Wang Q, van Wijk RC, Zhang N, Deitchman A, Nuermberger E, Savic RM. Ernest JP, et al. Among authors: nuermberger e. bioRxiv [Preprint]. 2023 Jan 20:2023.01.18.524608. doi: 10.1101/2023.01.18.524608. bioRxiv. 2023. Update in: Eur Respir J. 2023 Aug 31;62(2):2300165. doi: 10.1183/13993003.00165-2023 PMID: 36711493 Free PMC article. Updated. Preprint.
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis.
Römpp A, Treu A, Kokesch-Himmelreich J, Marwitz F, Dreisbach J, Aboutara N, Hillemann D, Garrelts M, Converse PJ, Tyagi S, Gerbach S, Gyr L, Lemm AK, Volz J, Hölscher A, Gröschel L, Stemp EM, Heinrich N, Kloss F, Nuermberger EL, Schwudke D, Hoelscher M, Hölscher C, Walter K. Römpp A, et al. Among authors: nuermberger el. Nat Commun. 2025 Jan 18;16(1):826. doi: 10.1038/s41467-025-56146-9. Nat Commun. 2025. PMID: 39827265 Free PMC article.
Contribution of telacebec to novel drug regimens in a murine tuberculosis model.
Komm OD, Tyagi S, Garcia A, Almeida D, Chang Y, Li S-Y, Castillo JR, Converse PJ, Black T, Fotouhi N, Nuermberger EL. Komm OD, et al. Among authors: nuermberger el. Antimicrob Agents Chemother. 2024 Dec 9:e0096224. doi: 10.1128/aac.00962-24. Online ahead of print. Antimicrob Agents Chemother. 2024. PMID: 39651910 Free article.
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.
Chang VK, Imperial MZ, Phillips PPJ, Velásquez GE, Nahid P, Vernon A, Kurbatova EV, Swindells S, Chaisson RE, Dorman SE, Johnson JL, Weiner M, Sizemore EE, Whitworth W, Carr W, Bryant KE, Burton D, Dooley KE, Engle M, Nsubuga P, Diacon AH, Nhung NV, Dawson R, Savic RM; AIDS Clinical Trial Group; Tuberculosis Trials Consortium. Chang VK, et al. Nat Commun. 2024 Oct 30;15(1):9400. doi: 10.1038/s41467-024-53273-7. Nat Commun. 2024. PMID: 39477924 Free PMC article. Clinical Trial.
Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.
Encinas L, Li S-Y, Rullas-Trincado J, Tasneen R, Tyagi S, Soni H, Garcia-Perez A, Lee J, González Del Río R, De Mercado J, Sousa V, Sosič I, Gobec S, Mendoza-Losana A, Converse PJ, Mdluli K, Fotouhi N, Barros-Aguirre D, Nuermberger EL. Encinas L, et al. Among authors: nuermberger el. Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0035724. doi: 10.1128/aac.00357-24. Epub 2024 Sep 30. Antimicrob Agents Chemother. 2024. PMID: 39345183 Free PMC article.
Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen.
Strydom N, Ernest JP, Imperial M, Solans BP, Wang Q, Tasneen R, Tyagi S, Soni H, Garcia A, Bigelow K, Gengenbacher M, Zimmerman M, Xie M, Sarathy JP, Yang TJ, Dartois V, Nuermberger EL, Savic RM. Strydom N, et al. Among authors: nuermberger el. Nat Commun. 2024 Aug 25;15(1):7311. doi: 10.1038/s41467-024-50781-4. Nat Commun. 2024. PMID: 39181887 Free PMC article. Clinical Trial.
226 results